Table 3.

Subgroup analysis of quality-of-life scores at 6 weeks and 3 months after surgery, stratified by adverse event severity

Empty Cell	Grade 0–1 adverse events		Grade ≥2 adverse events		p value*
Empty Cell	Patients, n	Mean score† (SD)	Patients, n	Mean score† (SD)	Empty Cell
FACT-Cx total score
6 weeks	357	78·0 (11·6)	78	73·2 (12·8)	0·0058
3 months	360	79·8 (12·9)	59	73·8 (13·3)	0·0023
SF-12: physical component
6 weeks	343	44·0 (6·4)	77	42·1 (7·3)	0·025
3 months	349	46·6 (5·8)	56	43·6 (7·3)	0·0051
SF-12: mental component
6 weeks	343	47·2 (6·9)	77	44·6 (7·8)	0·0016
3 months	349	45·5 (7·5)	56	44·5 (6·1)	0·38
MDASI: symptom score
6 weeks	357	86·8 (13·9)	78	80·5 (17·7)	0·0014
3 months	362	87·4 (14·8)	58	80·4 (18·2)	0·0092
MDASI: interference score
6 weeks	357	83·3 (20·6)	77	71·7 (26·2)	0·0002
3 months	360	87·6 (19·4)	57	78·3 (23·5)	0·026
EQ-5D body state score
6 weeks	354	80·6 (15·5)	80	73·2 (17·2)	0·0033
3 months	361	82·2 (16·1)	58	75·2 (21·5)	0·066

FACT-Cx=Functional Assessment of Cancer Therapy–Cervical. SF-12=12-item Short Form Health Survey. MDASI=MD Anderson Symptom Inventory. EQ-5D=EuroQoL-5D.

^*Two-sided.

^†All quality-of-life scores were transformed to a 0–100 scale, with higher scores indicating better quality of life.